Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.
about
Leukocyte migration and graft-versus-host disease.Depletion of host CCR7(+) dendritic cells prevented donor T cell tissue tropism in anti-CD3-conditioned recipients.NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.Advances in graft-versus-host disease biology and therapy.CCR7 expressing mesenchymal stem cells potently inhibit graft-versus-host disease by spoiling the fourth supplemental Billingham's tenetAdvances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationSphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.CCR2 is required for CD8-induced graft-versus-host disease.FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.Regulation of immunity by lysosphingolipids and their G protein-coupled receptorsRegulation of acute graft-versus-host disease by microRNA-155.Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Pathophysiology of acute graft-versus-host disease: recent advances.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD).FTY720 markedly increases alloengraftment but does not eliminate host anti-donor T cells that cause graft rejection on its withdrawal.The S1P1 receptor-selective agonist CYM-5442 reduces the severity of acute GVHD by inhibiting macrophage recruitment.Advances in the understanding of acute graft-versus-host disease.Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI.Absence of P-selectin in recipients of allogeneic bone marrow transplantation ameliorates experimental graft-versus-host disease.Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion.Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism.Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells.Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.Mouse models of graft-versus-host disease: advances and limitationsRegulatory T cells and IL-17-producing cells in graft-versus-host disease.New ways to separate graft-versus-host disease and graft-versus-tumour effects after allogeneic haematopoietic stem cell transplantation.Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.Novel targets in the treatment of chronic graft-versus-host disease.The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.In vivo engineering of mobilized stem cell grafts with the immunomodulatory drug FTY720 for allogeneic transplantation.CTLA4-CD28 chimera gene modification of T cells enhances the therapeutic efficacy of donor lymphocyte infusion for hematological malignancy.Sphingosine 1-Phosphate Signaling and Its Pharmacological Modulation in Allogeneic Hematopoietic Stem Cell Transplantation.The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease
P2860
Q30479618-743D6AC2-7E56-4A63-A501-DE7346BC9825Q33756801-B65F7E42-A4D1-401B-869B-5E49D38FE459Q33887452-67E8B0E7-5A7E-4EAE-ADFD-8CB1AE658C8BQ34031916-5A5523AC-043C-48D4-A772-B3AD1B3BB11AQ34790016-A7338C1C-BA58-4325-BE0F-00DB6153F351Q35586614-E566D860-1F91-42DE-BDD1-62D9C25DF4C8Q35675184-141E7058-E32C-430A-B07E-584446E0D638Q35844999-6C34EEC2-035C-4C3F-A178-923AEEAF7311Q35848441-C2EDB483-FB85-429E-B981-B364C74782EDQ35945171-C739684C-2E97-4CF5-A397-7F22C03F0BF1Q35971421-303D31B2-D584-4724-91F0-DF6A335AA997Q36010229-379EB5C8-3781-4CFB-881D-5515D2FB182DQ36130498-9B59462D-1F55-4A6B-BCFC-6407C914F665Q36156559-337A4304-7A80-488A-A186-CD3358D558D7Q36251308-6468A37F-D1D2-4F86-8D98-D14CF2D8298FQ36384836-9E25C2AB-1A74-45CF-A569-D6866EC4A853Q36462344-E3E97E55-BAE2-47F0-8877-1D6721B687C9Q36473213-16D87285-B7D9-4EE5-B9EC-1ABAB79D597AQ36759581-E542BFD0-E001-4606-B969-BDEF1C490C08Q37035815-29272D50-0664-48E6-ABEE-865B55995DEAQ37071152-3E810C17-937C-424B-A264-EF5E778C91DEQ37119275-337B8046-237C-4F6E-94EC-C9D29BFE607BQ37197925-0FFFBF8F-D52C-4882-B91A-07A845B0C723Q37211290-F1DD4ECD-C810-4645-9275-C4FC5AF1583FQ37223366-8F8B59B6-6987-4B31-9E6A-9E62992171F7Q37416883-3FF4FDDD-D26E-4A95-B4D2-BF9786DF7693Q37874011-B1153AAD-829D-4A98-A04D-06C05F61DECDQ37900645-C788DD0B-B55B-46A3-B2C2-D8F174A70764Q38057376-DC58B934-7360-4988-8D6D-A74933BCA3B2Q38736579-A373C9DC-7707-4BE9-8D91-69CF7F455B2EQ38905932-739911CB-0837-45F8-AA4C-80356C5FD352Q39023963-D4D7025F-630D-4C41-92F1-4C64824E5D2BQ39035437-50E2657F-F1AF-4A8D-9984-7B0ADD109675Q39161011-11F4D100-E397-4C1A-B031-4470172DEF7DQ40697115-8C0AFD8E-6CC2-49B0-A661-3597EDFBB671Q41480472-C73E9F06-6CCD-4A25-BA13-306CCB3D3421Q41995676-089120C3-428E-4FA9-B9E0-FE7E695B4382Q42151172-4E3E63CE-A9DB-4192-B6EC-F3A88DACD45BQ56901286-4017E8D0-612B-4AED-97C4-2FB6996EBBDC
P2860
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@ast
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@en
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@nl
type
label
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@ast
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@en
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@nl
prefLabel
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@ast
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@en
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@nl
P2093
P2860
P356
P1476
Graft-versus-host disease can ...... ocyte trafficking with FTY720.
@en
P2093
Megan Sykes
Roderick Bronson
Teviah Sachs
Wannee Asavaroengchai
Yong-Mi Kim
P2860
P304
P356
10.1172/JCI200316950
P407
P577
2003-03-01T00:00:00Z